The PneumoNP project aims at developing new inhaled nanotherapeutic formulations to combat lung infection. The novel drug is comprised of an antibiotic carried by a nanoparticle. For this project, Spanish researchers from CIC BiomaGUNE track the location of the therapeutic particles in rat airways.
The use of nanoparticles in formulations is anticipated to lengthen the residence time of the drug in lungs. Indeed, it is expected to slow down and control the release of the active molecules. This prevents rapid metabolism and fast clearance. So, the therapeutic effects are expected to increase. Besides, the delivery by inhalation contributes to diminish undesired toxicological and off-target side effects. The results obtained in imaging experiments are essential to establish the appropriate dosage to be used in therapeutic experiments with infected animals and to predict therapeutic efficacy.
The researchers have developed labeling methods to incorporate different radionuclides to the nanocarrier and the antibiotic. Thanks to the different physical properties of the radionuclides, they visualize the spatiotemporal distribution of the nanocarrier and the antibiotic separately. To achieve that they also used complementary in vivo imaging modalities.
Source: Read Full Article